Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company developing therapies for rare genetic skin diseases, has been added to the Russell 3000® Index and Russell 2000® Index as part of the 2025 Russell indexes reconstitution, effective June 30, 2025.
The Russell indexes, which are widely used by investment managers and institutional investors, have approximately $10.6 trillion in assets benchmarked against them as of June 2024. Membership in these indexes is determined by market capitalization rankings and style attributes, with the Russell 3000® capturing the 3,000 largest US stocks.
Palvella Therapeutics (Nasdaq: PVLA), un'azienda biofarmaceutica in fase clinica che sviluppa terapie per malattie genetiche rare della pelle, è stata inclusa nel Russell 3000® Index e Russell 2000® Index nell'ambito della ristrutturazione degli indici Russell 2025, con effetto dal 30 giugno 2025.
Gli indici Russell, ampiamente utilizzati da gestori di investimenti e investitori istituzionali, rappresentano circa 10,6 trilioni di dollari in asset a giugno 2024. L'appartenenza a questi indici è determinata dalla classifica della capitalizzazione di mercato e dagli attributi di stile, con il Russell 3000® che include le 3.000 maggiori azioni statunitensi.
Palvella Therapeutics (Nasdaq: PVLA), una compañía biofarmacéutica en etapa clínica que desarrolla terapias para enfermedades genéticas raras de la piel, ha sido añadida al Russell 3000® Index y Russell 2000® Index como parte de la reconstitución de los índices Russell 2025, con efecto a partir del 30 de junio de 2025.
Los índices Russell, ampliamente utilizados por gestores de inversiones e inversores institucionales, cuentan con aproximadamente 10,6 billones de dólares en activos referenciados a junio de 2024. La membresía en estos índices se determina por la clasificación de capitalización de mercado y atributos de estilo, siendo el Russell 3000® el índice que agrupa las 3,000 mayores acciones de EE. UU.
Palvella Therapeutics (나스닥: PVLA)는 희귀 유전성 피부 질환 치료제를 개발하는 임상 단계의 바이오제약 회사로, 2025년 러셀 지수 재구성의 일환으로 러셀 3000® 지수 및 러셀 2000® 지수에 2025년 6월 30일부터 편입되었습니다.
러셀 지수는 투자 관리자 및 기관 투자자들 사이에서 널리 사용되며, 2024년 6월 기준 약 10.6조 달러의 자산이 이 지수를 벤치마크로 활용하고 있습니다. 이 지수의 구성은 시가총액 순위와 스타일 속성에 따라 결정되며, 러셀 3000®은 미국 내 가장 큰 3,000개 주식을 포함합니다.
Palvella Therapeutics (Nasdaq : PVLA), une entreprise biopharmaceutique en phase clinique développant des thérapies pour des maladies génétiques rares de la peau, a été ajoutée aux indices Russell 3000® et Russell 2000® dans le cadre de la reconstitution des indices Russell 2025, effective au 30 juin 2025.
Les indices Russell, largement utilisés par les gestionnaires d'investissements et les investisseurs institutionnels, représentent environ 10,6 billions de dollars d'actifs en référence à juin 2024. L'appartenance à ces indices est déterminée par le classement de la capitalisation boursière et les caractéristiques de style, le Russell 3000® regroupant les 3 000 plus grandes actions américaines.
Palvella Therapeutics (Nasdaq: PVLA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das Therapien für seltene genetische Hauterkrankungen entwickelt, wurde im Rahmen der Neustrukturierung der Russell-Indizes 2025 zum 30. Juni 2025 in den Russell 3000® Index und Russell 2000® Index aufgenommen.
Die Russell-Indizes, die von Investmentmanagern und institutionellen Anlegern weit verbreitet genutzt werden, umfassen zum Juni 2024 etwa 10,6 Billionen US-Dollar an verwalteten Vermögenswerten. Die Zugehörigkeit zu diesen Indizes wird anhand von Marktkapitalisierungs-Rankings und Stilmerkmalen bestimmt, wobei der Russell 3000® die 3.000 größten US-Aktien abbildet.
- Inclusion in widely-followed Russell 3000® and Russell 2000® Indexes increases visibility to institutional investors
- Automatic inclusion in appropriate growth and value style indexes provides broader market exposure
- None.
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has been added to the broad-market Russell 3000® Index and the Russell 2000® Index, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution.
Annual Russell indexes reconstitution captures the 3,000 largest US stocks, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which currently remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from ongoing clinical trials, Palvella’s clinical development plans and related anticipated development milestones, Palvella’s cash and financial resources and expected cash runway, and the potential of, and expectations regarding, Palvella’s programs, including QTORIN™ rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN™ rapamycin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com
FAQ
What indexes was Palvella Therapeutics (PVLA) added to in June 2025?
What is Palvella Therapeutics' (PVLA) main business focus?
How long will Palvella Therapeutics (PVLA) remain in the Russell 3000® Index?
How many assets are benchmarked against the Russell US indexes?
